RUNX1 and neoplasm: Ro5‐3335 is a small‐molecule inhibitor that impairs RUNX1‐mediated transcriptional activity and has shown a favorable safety profile in mice.[35] Moreover, Ro5‐3335 has demonstrated therapeutic potential in various tumor types other than CRC.[36, 37, 38] We found that Ro5‐3335 treatment significantly reduced liver metastatic burden in mice bearing MC38‐LM3b‐shScramble cells.